Welcome to our dedicated page for Nyxoah S.A. news (Ticker: $NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah S.A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nyxoah S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nyxoah S.A.'s position in the market.
Nyxoah reported financial and operating results for Q1 2024 on May 14, 2024. Key highlights include the DREAM U.S. pivotal study achieving co-primary endpoints, with a median AHI reduction of 70.8% and a 12-month AHI responder rate of 63.5%. The company recorded €1.2 million in sales, a 170% increase from Q1 2023. However, the operating loss increased to €12.2 million from €11.4 million last year mainly due to higher R&D expenses. The cash position was €44.3 million, down from €57.7 million at the end of 2023. CEO Olivier Taelman emphasized the positive study results and the company's readiness for a U.S. launch by the end of 2024.
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a medical technology company, will release its Q1 2024 financial results on May 14, 2024, after the market closes. The announcement will be followed by a conference call at 10:30pm CET / 4:30pm ET to discuss the results.
The webcast of the call can be accessed via the Nyxoah Investor Relations page. Pre-registration is required for those wishing to ask questions during the call, with an email providing dial-in details and a unique access code for the live call to follow. The webcast will be available for replay shortly after the event concludes.
The press release announces the invitation to attend the annual and extraordinary shareholders' meetings of NYXOAH SA, a company listed on Euronext Brussels under the symbol NYXH, to be held on June 12, 2024. The meetings will address various agenda items including approval of financial statements, discharge of directors and auditors, approval of remuneration report, and appointment of directors. Shareholders can participate in person or via video conference by following specified registration and voting procedures. The press release provides detailed information on formalities, participation requirements, voting procedures, and data processing related to the meetings.
